Osteopenia: a key target for fracture prevention

Area of Science:

• Gerontology
• Bone Metabolism
• Radiology

Background:

• Osteopenia was initially a qualitative radiographic term for reduced bone density.
• Since 1994, osteopenia is quantitatively defined by a bone mineral density (BMD) T-score between -1.0 and -2.5.
• Over 60% of White women over 64 years old have osteopenia, representing a significant demographic.

Purpose of the Study:

• To review the evidence concerning the management of older adults diagnosed with osteopenic bone densities.
• To emphasize the role of bone mineral density (BMD) in quantitative fracture risk assessment.
• To evaluate the efficacy and cost-effectiveness of bisphosphonates in reducing fractures in osteopenic individuals.

Main Methods:

• Assessment of existing clinical trial evidence on osteopenia management.
• Analysis of fracture risk factors within the osteopenic range, including BMD, age, and history.
• Evaluation of the cost-effectiveness of bisphosphonate therapies for older osteopenic women.

Main Results:

• Most fractures occur in osteopenic individuals due to their large numbers, despite lower individual risk compared to osteoporosis.
• Fracture risk in osteopenia is highly variable, influenced by BMD, age, fracture history, and ethnicity.
• Oral and intravenous bisphosphonates have demonstrated cost-effective fracture reduction in older osteopenic women.

Conclusions:

• Osteopenia diagnosis alone is insufficient for intervention or reassurance; BMD must be integrated into fracture risk calculations.
• A 10-15% major osteoporotic fracture risk may justify treatment with generic bisphosphonates in motivated individuals over 65.
• Management strategies for older adults with osteopenic bone densities should incorporate quantitative fracture risk assessment and evidence-based therapies.